YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial

Review summary

Reports a phase 1/2 trial of VT3989, a YAP/TEAD pathway inhibitor, in solid tumors — assessing safety and early activity of targeting the Hippo pathway.